Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica’s proprietary technology targets the inhibition of disease-activated CRAC channels to modulate the immune response and protect against tissue cell injury, potentially providing therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies.

Learn More

Stock Information

Minimum 15 minutes delayed. Source: LSEG

Featured Events

View all Events

Corporate Presentation

View Presentation

Press Releases

24 Jun 26

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H
24 Jun 26

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026 /PRNewswire/ --
12 May 26

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected
03 Mar 26

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026 JCI Insight publication of preclinical
View all Releases
Explore More
Our Technologies
Our Pipeline
Our Story
Our Team